Stocksigma LogoStocksigma Logo

Symbiotec Pharmalab Receives US FDA EIR with VAI Status for Pithampur Facility

Symbiotec Pharmalab Limited received an Establishment Inspection Report from the U.S. FDA on 29th Sep'26 for its manufacturing facility located at

Symbiotec Pharmalab Receives US FDA EIR with VAI Status for Pithampur Facility

Symbiotec Pharmalab Ltd 路 Others (Uncategorized) 路 29 Sept 2026, 4:22 pm

Symbiotec Pharmalab Receives US FDA EIR with VAI Status for Pithampur Facility Symbiotec Pharmalab Limited received an Establishment Inspection Report from the U.S. FDA on 29th Sep'26 for its manufacturing facility located at Pithampur (SEZ), Madhya Pradesh. The regulatory agency classified the inspection outcome as Voluntary Action Indicated (VAI). This follows the regulatory audit conducted at the manufacturing site between 10th Aug'26 and 14th Aug'26, successfully resolving the inspection cycle and supporting ongoing regulatory compliance for U.S. market supplies.

Original exchange filing (PDF)

More announcements from Symbiotec Pharmalab Ltd

All Symbiotec Pharmalab Ltd announcements